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Abstract
Secretory Phospholipase A2 of type IIA (sPLA2 IIA) plays a crucial role in the production of
lipid mediators by amplifying the neointimal inflammatory context of the vascular smooth
muscle cells (VSMCs), especially during atherogenesis. Phenformin, a biguanide family
member, by its anti-inflammatory properties presents potential for promoting beneficial
effects upon vascular cells, however its impact upon the IL-1β-induced sPLA2 gene expres-
sion has not been deeply investigated so far. The present study was designed to determine
the relationship between phenformin coupling AMP-activated protein kinase (AMPK) func-
tion and the molecular mechanism by which the sPLA2 IIA expression was modulated in
VSMCs. Here we find that 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleotide (AICAR)
treatment strongly repressed IL-1β-induced sPLA2 expression at least at the transcriptional
level. Our study reveals that phenformin elicited a dose-dependent inhibition of the sPLA2
IIA expression and transient overexpression experiments of constitutively active AMPK
demonstrate clearly that AMPK signaling is involved in the transcriptional inhibition of
sPLA2-IIA gene expression. Furthermore, although the expression of the transcriptional
repressor B-cell lymphoma-6 protein (BCL-6) was markedly enhanced by phenformin and
AICAR, the repression of sPLA2 gene occurs through a mechanism independent of BCL-6
DNA binding site. In addition we show that activation of AMPK limits IL-1β-induced NF-κB
pathway activation. Our results indicate that BCL-6, once activated by AMPK, functions as
a competitor of the IL-1β induced NF-κB transcription complex. Our findings provide insights
on a new anti-inflammatory pathway linking phenformin, AMPK and molecular control of
sPLA2 IIA gene expression in VSMCs.
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Introduction
Phenotypic modulation of vascular smooth muscle cells (VSMCs) observed in the pathogenesis
of vascular diseases such as hypertension, restenosis, aneurysm and atherosclerosis is charac-
terized by the downregulation of the expression of VSMC-specific marker genes concomitant
with the upregulation of the expression of genes regulating proliferation, migration and secre-
tion of inflammatory mediators [1,2,3]. Atherosclerosis is a complex pathological process and
accumulating evidences indicate that cardiovascular disorders are closely associated with
chronic inflammation linked most often to metabolic syndrome which includes abdominal
obesity, atherogenic dyslipidemia, elevated blood pressure and insulin resistance [4,5]. In vivo
correlative data indicate that VSMCs, beside macrophages, play also an important role in the
initiation of atherosclerosis [6]. After migration from the media to the intima, VSMCs present
atherogenic properties. Hence, they are the major producers of extracellular matrix that in turn
provoke cell adhesion and oxidized low density lipoproteins accumulation [7]. The initiation
of atherosclerosis results from complex interactions of circulating inflammatory mediators.
VSMCs, endothelial cells, and macrophages produce a myriad of proatheogenic proinflamma-
tory and prothrombogenic molecules including lipid mediators such as various forms of eicosa-
noides, mainly prostaglandin E2 (PGE2) which in turn amplify the effects of cytokines [8,9].
Several observations argue for a major implication of type IIA secretory PLA2 (sPLA2-IIA)
[10]. Phospholipase A2 enzymes (EC 3.1.1.4) hydrolyze ester bonds at the sn-2 position of gly-
ceroacylphospholipids to produce lysophospholipids and nonesterified fatty acids such as ara-
chidonic acid (C20:4 n-6), the precursor of these proinflammatory mediators encompassing
PGE2 [11,12]. The isoform sPLA2 IIA gene (sPla2g2a) is largely expressed in VSMCs in
response to cytokines, interleukin-1β (IL-1β), IL-6 and tumor necrosis factor alpha (TNF–α)
[13]. We have shown that oxysterols, PGE2, high mobility group B1 (HMGB1) and serum
amyloid A (SAA) also induce sPLA2 IIA gene transcription in VSMCs [14, 9,15–16]. The inter-
play of various transcription factors (NF-κB, C/EBPβ, Ets, LXR, AP1) that stimulate the rat
sPLA2 promoter activity by these inducers has been demonstrated [14,17]. More recently, we
demonstrated that peroxisome proliferator-activated receptor (PPAR)-α,-γ,-β significantly
inhibited cytokine-stimulated sPLA2 expression and secretion in VSMCs [18]. However,
unlike to PPARα and γ, the inhibitory effect of PPARβ ligands was not affected by PPRE muta-
tion. In concordance with primary results of Lee et al [19], we demonstrated that PPARβ ligand
promotes B cell lymphoma 6 (BCL-6) binding to its specific sequence element in proximal
position of the sPLA2IIA gene promoter. Repression mechanisms triggered by BCL-6 have
been investigated in multiple cell systems. Interaction with histone-deacetylases, association
with various corepressors SMRT/NCoR, SIN3A [20] and proximate binding to NF-κB
response elements have been demonstrated [21]. Importantly, promoter structure as well con-
densation of binding sites driven induction of this sPla2g2a gene illustrate the pathological con-
sequences of losing BCL-6 repression in time course of chronic inflammation.
Interestingly, anti-hyperglycemic agents currently prescribed to treat type 2 diabetes, i.e.
biguanides such as metformin and phenformin, induce gene expression changes in the liver
including Bcl6 [22] and activate the highly conserved AMP-activated protein kinase (AMPK)
[23–24]. AMPK traditionally activated by increase in cellular AMP/ATP ratio, has been pro-
posed to function as a metabolic master switch to coordinate cellular adaptation to nutritional
and environmental variations[25–26]. AMPK, considered as an energy-sensing system, occurs
as heterotrimeric complexes which is only active after phosphorylation of a critical threonine
(Thr 172) in the activation loop of the α catalytic subunit. Upstream kinases have been identi-
fied as the tumor suppressor liver kinase B1 (LKB1) associated to STRAD and MO25 accessory
subunits [27–29] and the calmodulin-dependent protein kinase kinase-β (CaMKKβ) [30–31].
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The binding of AMP to the γ subunit of AMPK hinder the dephosphorylation of Thr 172 by
protein phosphatase. Recently, AMPK pathway appeared to be a critical downstream mediator
for vascular adiponectin signalling in endothelial cells and macrophages [32–33]. In addition,
the AMPK activator, AICAR (5-aminoimidazole-4-carboxamide-1-β-D-riboside), suppressed
serum-induced proliferation of human aortic SMCs [34] and mediated the modulation of leu-
cocyte adhesion observed onto aortic endothelial cells. Therefore, AMPK activation makes up
a potential anti-atherogenic mechanism [35].
The study was performed to determine the impact of the AMPK signaling pathway in the
regulation by biguanides of the sPLA2 IIA gene expression in VSMCs. As shown in the liver
with phenformin, we hypothesize that BCL-6 may serve as a target for the control of the sPLA2
gene expression. We demonstrate here that AMPK activation significantly inhibited cytokine-
stimulated sPLA2 promoter. Thus, the anti-inflammatory effect of AMPK could represent a
promising therapeutic target to limit the sPLA2-dependent production of proinflammatory
lipid mediators, namely PGE2, in the vascular wall.
Materials and Methods
Isolation and culture of VSMCs from rat aortas
VSMCs were isolated from thoracic aortas of adult male Wistar rats by enzymatic digestion as
described previously [36,17]. Cells were seeded on dishes coated with type I collagen from calf
skin (Sigma) and cultured in DMEM, 4mM glutamine, 100U/ml penicillin and 100μg/ml strep-
tomycin, supplemented with 10% (vol/vol) fetal calf serum (Gibco BRL). Experiments were
performed with confluent cells made quiescent by incubating them for 24h in serum-free
medium containing 0.2% SVF before treatment with appropriate agents for 24h. The culture
medium was then removed for measurements of sPLA2 activity and cells were lysed for total
RNA preparation and western blotting. Experiments with animals and cell culture were con-
ducted in accordance with guidelines of the "Haut Conseil des Biotechnologies" committee and
according to the accepted project "OGM" with the agreement from October 11–2011. Agree-
ment number: 5876. All procedures involving animal handling and their care were in accor-
dance with the University Pierre and Marie Curie Guidelines for Husbandry of Laboratory
Mice.
PLA2 activity
sPLA2 activity was measured using the fluorescent substrate 1-hexadecanoyl-2-(1-pyrenylde-
canoyl)-sn-glycero-3-phosphoglycerol (Interchim, France) as described previously [36]
Total hydrolysis of the substrate obtained with 0.1 unit of PLA2 from bee venom (Sigma) was
used as reference to calculate the sPLA2 activity in the samples. The basal level fluctuates fol-
lowing the preparation of VSMCs albeit the response to cytokine was of the same order until
the 5th passage where the induction becomes less intense reflecting a progressive loss of
differentiation.
RNA extraction and qRT-PCR analysis
Total RNA was extracted by using RNAeasy kit (Qiagen) according to the supplier’s instruc-
tions. Total RNA (1μg) was used as template to synthesize for 1h at 37°C the first strand cDNA
with 200 U of mouse mammary lentivirus-reverse transcriptase (RT) (Invitrogen), 100μM ran-
dom primers and the buffer supplied by the manufacturer in a total volume of 20μl. The reac-
tion was terminated by heating to 95°C for 5 min. Quantitative PCR was performed using the
LightCycler LC480 (Roche Diagnostics). The PCR mix included 5 μl of each complementary
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DNA (cDNA) (diluted 1:25) and 300 nM of each primer in 1× LightCycler DNA SYBR Green
1 Master Mix. The forward and reverse primer sequences for cDNA were designed with the
Primer Express software according to European Molecular Biology Laboratory accession num-
bers: the rat sPLA2-IIA, 5’-ATGGCCTTTGGCTCAAT-3’ (Ex1-2) and 5’-GCAACCGTA
GAAGCCATA-3’ (Ex2); the rat cyclophilin A, 5’-TGCTGGACCAAACACAAATG-3’ (Ex4)
and 5’-CTTCCCAAAGACCACATGCT-3’ (Ex5). The q-PCRs were performed using the fol-
lowing thermal settings: denaturation and enzyme activation at 95°C for 5 minutes, followed
by 40 cycles of 95°C (10s), 60°C (15s), and 72°C (15s). Post-amplification dissociation curves
were performed to verify the presence of a single amplification product and the absence of
primer dimers. Controls and water blanks were included in each run; they were negative in all
cases. Real-time quantitative PCR data represent the amount of each target messenger RNA
(mRNA) relative to the amount of cyclophilin gene mRNA, estimated in the logarithmic phase
of the PCR. Serial dilutions were used to determine the fit coefficients of the relative standard
curve.
Western blotting
VSMCs were harvested, homogenized in a lysis buffer at 4°C and centrifuged as described [18].
Proteins (20 μg/lane), evaluated using Quick Start Bradford protein assay from Biorad, were
separated on SDS-PAGE gel electrophoresis (8% gel). After electroblotting onto nitrocellulose
Amersham Hybond-ECL (GE Heathcare) we determined the efficiency of the protein transfer
with Ponceau S (Sigma-Aldrich). After blocking with 5% non-fat dry milk in Tris Buffered
Saline (TBS) the membrane was incubated overnight with specific antibodies, P-AMPKα
(Thr172), AMPKα, P-acetyl-CoA carboxylase (Ser79) and acetyl-CoA carboxylase, BCL-6,
phospho-IκBα, β-actin, phospho-IκBα, I-κBα, phospho-p65 and p-65 NF-κB (Cell Signaling
Technology) in TBS containing 0.1% tween 20. After three successive 10 min washes the blot
was incubated 1 h with HRP conjugated (Sigma) secondary antibody (1:2000) in TBS contain-
ing 0.1% tween 20. Detection of immune complexes was visualized using enhanced chemilumi-
nescence reagents onto an Image captur Las 3000 (Fujifilm).
Plasmid transfection
VSMCs were seeded 48 h before transfection in 24 well plates at a concentration of 2x104 cells
per plate in DMEM (2% glutamine, 1% penicillin-streptomycin, 10% SVF). At 70% confluence
cells were washed 20 min before transfection. The transfection mixture was as follow: 400ng of
luciferase reporter DNA [-1153; +46]sPLA2-Luc or multimeric-NF-κB[(Ig-κB]-Luc already
described, 100ng of CMVβ-galactosidase, 1.6μl of Lipofectamine plus and Lipofectamine (Invi-
trogen) in 200μl of OPTIMEM (Sigma) and for transactivation studies 10ng of pCMV-AMPKα2
catalytic and negative dominant expression vector were added to the mix. The cells were refed
3h later with 200μl of DMEM containing 5% SVF for 1h and then the culture medium was
replaced by DMEM containing 0.2% SVF. Twenty hours later after the start of the transfection,
the medium was changed and the cells were pretreated with indicated concentration of AICAR
(5-aminoimidazole-4-carboxamide-1-β–D-riboside), phenformin (phenylbiguanide) for 4h,
then stimulated with IL-1β (10ng/ml) and the incubation was continued for a further 24h. Lucif-
erase activity was measured using luciferase reporter assay kit (PROMEGA), with signal detec-
tion for 12s by a luminometer (Berthold, Pforzheim, Germany) and normalized by dividing the
relative light units by β-galactosidase activity. The degree of induction was calculated relative to
the control (minus IL-1β).
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Statistical analysis
All quantitative data are presented as mean of at least 3 independent experiments ± SEM. Sta-
tistical analyses were performed using an unpaired Student’s t-test and comparisons involving
repeated measurements were analyzed by repeated-measures ANOVA followed by Bonferroni
posttest. Results are expressed as the means +/- SE. Differences were considered significant at
P<0.05.
Results
AICAR and phenformin activate AMPK in rat VSMCs
Experiments were conducted with primary cultures of VSMCs isolated from rat aorta. These
cells undergo phenotypic changes in response to proinflammatory conditions. Indeed, in
response to proinflammatory cytokines, these cells express several biomarkers of inflammation
such as VCAM-1, MCP1, extracellular metalloproteinases and acute phase enzymes such as
secreted sPLA2 and COX-2 [7,37–39]. Moreover, we have previously observed that prostaglan-
dins E2 combined with IL-1β progressively synergizes the secretion of sPLA2 and causes a
complete disorganization of the cytoskeletal framework [9]. To explore the effect of AMPK
activation on IL-1β-induced sPLA2IIA gene expression and activity, cultured VSMCs were
pretreated or not with the AMPK activators AICAR or phenformin prior IL-1β treatment. We
chose to use phenformin which is more lipophilic than metformin and more efficiently inter-
nalized in cell culture in absence of cationic transporters. We performed immunoblotting to
show whether treatment with AICAR or phenformin led to the activation of AMPK, character-
ized by the phosphorylation of Thr172 within the AMPKα subunit and of Ser79 in acetyl-coA
carboxylase (ACC), a well-established target of AMPK [26]. As shown in Fig 1, treatment of
VSMCs with 2mM AICAR or 1mM phenformin led to a significant increase in Thr172 AMPK
and Ser79 ACC phosphorylation. In the presence of IL-1β, AICAR and phenformin induced
phosphorylation of both Thr172 AMPK and Ser79 ACC. These results confirm that AICAR
and phenformin stimulate AMPK signaling pathway in primary cultured rat VSMCs, consis-
tent with previous studies showing AMPK activation by the biguanide metformin in BAECs or
HUVECs [40].
AICAR and phenformin inhibit IL-1β-induced sPLA2-IIA gene expression
and activity
Next, in order to investigate whether AMPK might hinder the IL-1β-induced production of
sPLA2, cultured rat VSMCs were pretreated with AICAR or phenformin prior to be incubated
with IL-1β. Clearly, AICAR dose-dependently caused a significant inhibition of IL-1β-induced
sPLA2 activity secreted by VSMCs, whereas it has no effect on basal sPLA2 activity in the
absence of IL-1β (Fig 2A). We observed that AICAR strongly inhibited IL-1β-induced sPLA2
IIA gene expression as soon as 3 hours after IL-1β treatment (Fig 2B). This result indicates that
activation of AMPK pathway for 4 hours was optimal for complete inhibition of the IL-1β
induced sPLA2 gene expression. Similarly, incubation with phenformin resulted in a progres-
sive dose-dependent decrease in IL1β-induced sPLA2 activity secreted in the culture medium
(Fig 3A) and significantly lowered IL-1β-induced expression of sPLA2 IIA to the basal level
(Fig 3B). Our results showed that AICAR and phenformin are both potent anti-inflammatory
agents that suppress sPLA2 IIA production in rat VSMCs incubated with IL-1β.
Inhibition of sPLA2IIA Expression by AMPK Signaling
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AMPK activation represses sPLA2 IIA promoter activity in VSMCs
Since, phenformin and AICAR modulate IL1β-induced sPLA2 IIA gene expression in rat
VSMCs, these results prompted us to examine the ability of AMPK to regulate the sPLA2 pro-
moter activity. We have previously characterized the interplay of various transcription factors
involved in the modulation of sPLA2 promoter activity [17–18]. Interestingly, all the binding
sites were conserved and perfectly aligned between human and rat promoters (Fig 4A). A
reporter construct encompassing the rat sPLA2 promoter ([-1153; +46]sPLA2-Luc) was tran-
siently transfected into VSMCs preincubated with phenformin or AICAR for 4 hours prior to
the treatment with IL-1β (10ng/ml) for 18 hours. We observed that the activity of the sPLA2
promoter was significantly decreased in a dose dependent manner with phenformin and drasti-
cally with AICAR (Fig 4B). In an attempt to determine the role of AMPK activation on the
sPLA2 promoter activity, we expressed constitutively active (CA-AMPK) or dominant negative
(DN-AMPK) AMPK mutants in VSMCs [41]. Expression of CA-AMPK strongly decreased
the [-1153; +46]sPLA2 promoter induction by IL-1β (Fig 4C). Addition of 2mM AICAR in
the cell culture medium did not show additive inhibitory effect with expression of
CA-AMPK, indicating that AICAR signals through the AMPK signaling pathway to inhibit
sPLA2 promoter activity. In contrast, expression of DN-AMPKα2 has no effect on basal and
IL-1β-induced sPLA2 promoter activity but severely blunted the inhibitory action of AICAR
on IL-1β-induced sPLA2 promoter activity, excluding off-target effect of AICAR (Fig 4D).
Altogether, the experiments indicate that activation of AMPK exerts a repressive effect on
Fig 1. AICAR and phenformin treatments induce the phosphorylation of AMPK and ACC in isolated rat VSMCs in primary culture. After 1 hour
pretreatment with AICAR (2mM) or phenformin (1mM), the cells were incubated or not with IL-1β (10ng/ml) for 30 minutes. Total proteins (20μg/lane) were
separated by SDS PAGE and western blotted with specific antibodies (part A) against phospho-AMPK, total AMPK (65 KDa), and (part B) phospho-ACC,
total ACC. β–actin was used as loading control. Representative blots of 3 independent experiments are shown. Data of the quantification are expressed as
mean +/- SEM. *, p < 0,05; **, p < 0,01, AICAR or Phenformin treated vs control cells.
doi:10.1371/journal.pone.0132498.g001
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IL-1β-stimulated expression of the type IIA sPLA2 gene in VSMCs. As a consequence, AMPK
stimulation may reduce the extended production of proinflammatory mediators as lysopho-
spholipids and arachidonic acid.
Fig 2. AICARmodulates IL-1β-induced sPLA2 activity and sPLA2 IIA mRNA expression in rat VSMCs. (A) VSMCs were preincubated for 4 hours with
various concentrations of AICAR and then cultured in absence or presence of IL-1β (10ng/ml) for 18 hours. The sPLA2 activity was measured
spectrofluorimetrically from the supernatant of the cells. (B) Cells were preincubated for 4 hours with 2mM AICAR and then treated with IL-1β for 3, 6 or 9
hours. Total RNA was extracted and real time PCR was performed to evaluate sPLA2mRNA levels as described under Experimental procedures. Data are
shown as mean +/- SEM from 3 separate experiments. *, p<0.01;**, p <0.001, IL-1β–treated vs control cells, IL-1β-treated vs control cells; #, p< 0.001
AICAR treated vs IL-1β treated VSMCs.
doi:10.1371/journal.pone.0132498.g002
Inhibition of sPLA2IIA Expression by AMPK Signaling
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Role of BCL6 as repressor stimulated by AICAR
We previously showed that VSMCs expressed the proto-oncogene BCL-6 and demonstrated its
ability to repress the expression of sPLA2 IIA [18], in concordance with results reported with
another proinflammatory gene, MCP1 in macrophages [19]. We first determined the expres-
sion of BCL-6 in rat VSMCs by Western blot analysis. As already observed its expression was
slightly augmented in the presence of IL-1β. BCL-6 expression was further increased in the
presence of AICAR and phenformin concomitantly with AMPK signalling activation (Fig 5A).
This finding led us to specifically consider the repressor, BCL-6, as a potential target of the
AMPK pathway. We previously demonstrated that PPARβ agonist (L165041) elicited the bind-
ing of BCL-6 to the sPLA2 promoter and led to its inhibition under inflammatory conditions
[18]. In an attempt to examine the role of BCL-6 binding site in the regulation of sPLA2IIA
promoter transcription, VSMCs were transiently transfected with the [-1153; +46]sPLA2 pro-
moter in which BCL-6 binding site was mutated in combination or not with mutation in the
PPRE binding site. Mutation of BCL6 binding site in the [-1153; +46]sPLA2 promoter strongly
increased sPLA2IIA promoter activity in basal condition, confirming the repressive role of
BCL6 on sPLA2 gene expression. Interestingly, incubation of VSMCs with AICAR yielded to
the same levels of inhibition observed with mutPPRE or the mutBCL-6 constructs as the wild
type construct, [-1153; +46]sPLA2 in basal and IL-1β-stimulated conditions, suggesting that
BCL-6 and PPRE binding sites are not necessary for the repression of sPLA2IIA promoter by
AMPK (Fig 5B). As we previously demonstrated that PPARβ agonist (L165041) induced a
BCL-6 binding to the sPLA2 promoter under inflammatory conditions, we performed transient
transfection in the presence of either PPARβ ligand or AICAR or both. We observed that the
IL-1β-induction of the [-1153; +46]sPLA2 promoter was attenuated to similar levels by PPARβ
ligand and AICAR (Fig 5C). Importantly, this inhibition was further enhanced by co-treatment
with PPARβ ligand and AICAR (Fig 5C). When activity of the mutBCL-6[-1153; +46]sPLA2
promoter was examined in the presence of IL1β, the inhibitory effect of PPARβ ligand was
abolished but in contrast the inhibitory effect of AICAR alone or in combination with PPARβ
ligand was preserved (Fig 5D). Altogether, these results suggest that the ability of AMPK to
inhibit the sPLA2IIA promoter is independent on the BCL-6 binding site.
Fig 3. Effect of phenformin and AICAR treatment on sPLA2 activity and gene expression in rat VSMCs. VSMCs were preincubated for 4 hours with
phenformin (0.1, 0.5, 1, 5mM) and AICAR (2mM) and cultured in absence or presence of IL-1β (10ng/ml) for 18 hours. (A) sPLA2 activity was measured in
the supernatant of cells. (B) sPLA2mRNA levels were determined by real time PCR analysis. Data are shown as mean +/- SEM from 3 separate
experiments. *, p<0,01; **, p<0,001, IL-1β and Phenformin or AICAR treated vs IL-1β-treated cells.
doi:10.1371/journal.pone.0132498.g003
Inhibition of sPLA2IIA Expression by AMPK Signaling
PLOS ONE | DOI:10.1371/journal.pone.0132498 July 10, 2015 8 / 18
Inhibition of IL-1β-induced NF-κB dependent transactivation by AMPK in
VSMCs
The absence of AICAR and phenformin action through the BCL-6 binding site on the sPLA2
promoter (Fig 6A) prompted us to further investigate whether AMPK acts on another regula-
tory site. We demonstrated previously that the sPLA2 gene promoter contains a crucial NF-κB
binding site at position -131bp which is crucial for the stimulation of sPLA2 promoter by IL-1β
[17]. It was recently shown that AICAR and a constitutively active AMPK reduced the expres-
sion of VCAM-1 in TNFα-activated aortic endothelial cells by attenuating NF-κB acetylation
[41–42]. In order to assess the impact of phenformin and AICAR on the activity of the tran-
scriptional factor NF-κB in VSMCs, we transiently transfected VSMCs with a chimeric con-
struct, [(IgKB)3-cona]-Luc, where 3 IgK enhancer κB sites were fused to the conalbumin
promoter [43,17]. The activity of the chimeric NF-κB-Luc promoter was also strongly dimin-
ished with AICAR and phenformin treatment (Fig 6B). This result reveals that the treatment of
VSMCs by either AICAR or phenformin abolished the IL-1β-induced activity of a promoter
which transcription was strickly dependent upon the NF-κB pathway. To further confirm the
impact of AICAR and phenformin on the activation of NF-κB transcription factor by IL-1β,
Fig 4. Phenformin, AICAR and overexpression of the AMPKα2 subunit inhibit the sPLA2 IIA gene promoter activity in VSMCs. (A) Alignment of rat
(R) and human (H) NFκB, C/EBP, BCL-6, PPAR binding sequences of the sPLA2 IIA gene promoters. (B) VSMCs were transitory transfected with
Lipofectamine plus with the sPLA2-Luc reporter plasmid: rat [-1153; +46]sPLA2 IIA-Luc construct. Cells were pretreated with phenformin (1 and 2 mM) or
AICAR (1 and 2 mM) for 4 hours before prolonged incubation for 18 hours with or without IL-1β (10 μg/ml). (C and D) VSMCs were cotransfected with 1 and
10 ng of pCMV AMPKα2 constitutively active or dominant negative expression vector. As a control cells were transfected with empty pcDNA3. After
transfection, cells were treated or not with IL-1β and AICAR (2mM) for 18 hours. The relative luciferase activities were calculated after normalization to β-
galactosidase activity. Results (mean +/- SEM) were from 3 independent experiments. *, P<0.05; **, P<0.01 compared with IL-1β treated cells.
doi:10.1371/journal.pone.0132498.g004
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we analyze degradation of NF-κB inhibitor IκBα and NF-κB translocation (Fig 6C). The blot
probed with antiphospho-IκB antibody shows a phosphorylated IκBα specific band detected in
IL-1β treated cells. When VSMCs where pretreated with AICAR and phenformin the impact of
IL-1β upon the phosphorylation of IκBα was diminished and the IL-1β induced phosphoryla-
tion of p65 protein was clearly attenuated. These results demonstrate that activation of AMPK
pathway interfere with IL-1β activation of the NF-κB signaling cascade. In consequence, the
activation of proinflammatory genes, encompassing a NF-κB binding site, like sPLA2 IIA gene
was strongly hindered in vascular SMCs.
Discussion
In the present study we investigated the anti-inflammatory properties of the AMPK activators,
AICAR and the antidiabetic drug phenformin, by focusing our attention on the modulation of
sPLA2 IIA gene expression by inflammatory signals in VSMCs. The above findings have war-
ranted a revisiting of the transcriptional regulation of the IL-1β-induced sPLA2 IIA gene
Fig 5. sPLA2 gene promoter inhibition is independent of the BCL-6 binding site in VSMCs. (A) protein expression was assessed byWestern blot
analysis, BCL-6 (95 KDa), phospho-AMPK-Thr 172 and AMPK (65 KDa). VSMCs were treated with IL-1β (10ng/ml) alone or with AICAR (2mM) or phenformin
(1mM) for 18 hours. (B) VSMCs were transfected with the sPLA2-Luc reporter plasmids: [-1153;+46]sPLA2Luc, mutated PPREsPLA2 (mutPPRE), mutated
BCL-6 site (mutBcl6), double-mutated version of the sPLA2 promoter (mutPPRE-Bcl6) and VSMCs were then treated as in Fig 4. (C) VSMCs were
transfected with the [-1153;+46]sPLA2Luc plasmid, treated with PPARβ ligand (L165041, 10mM) or 2mM AICAR or both 4 hours before addition or not of IL-
1β for an additional 18 hours. (D) VSMCs were transfected with BCL-6-mutated sPLA2 version, (mBCL-6[-1153;+46])sPLA2Luc construct and incubated as
in part C. Data are expressed as mean +/-SEM of 4 experiments. #, P<0.05 (compared with control) and *, P<0.05; **, P<0.01 compared with IL-1β treated.
doi:10.1371/journal.pone.0132498.g005
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promoter activity. Our results highlight new integrated molecular mechanisms involving
AMPK signaling pathway in the inhibition of sPLA2 IIA gene expression and provide new
insights through the interplay between the protooncogene BCL-6 and NF-κB transcription
factors.
Inflammation in the vascular intima has emerged as a crucial factor in the pathogenesis of
atherosclerosis induced by hypercholesterolemia, shear stresses of hypertension or disordered
blood flow and during restenosis after coronary intervention. Circumscribed chronic inflam-
matory states originate from a partial destruction of cells followed by a partial healing of the tis-
sue. The VSMCs proliferation and progressive dedifferentiation, is a critical event of the
progression of vascular neointimal lesion formation. Beside chemokines, several mediators as
biologically active oxidized lipids, named eicosanoids (mainly PGE2) are involved. These lipid
Fig 6. Phenformin and the activator of AMPK repress the sPLA2 gene promoter activity through NF-κB binding sites and inhibit IL-1β-induced NF-
κB activation. VSMCs were transfected with either mutated-BCL-6 sPL2 IIA-Luc reporter (part A) or a NFκB-mediated-Luc-reporter (part B) construct made
up a multimerized NF-κB binding site chimeric promoter and then incubated with phenformin (1 or 2 mM) and with AICAR (1 or 2 mM) in the same conditions
as Fig 5. Data are expressed as mean +/-SEM of 3 experiments. *, ** P<0.05 and P<0.01 respectively compared with IL-1β treated VSMs. In part C, IkBα,
phospho-IκBα, p65NF-κB and phospho-p65NF-κB expression was assessed by western blots. VSMCs were preincubated with or without AICAR (2mM) or
phenformin (2mM) for 30 minutes before addition of IL-1β (10ng/ml) for 15 minutes. Then the cells were harvested and lysed as described and subjected to
western blotting to detect phospho-ⅠBα, IκBα, phospho-p65NF-κB. Total. p65NF-κB is provided as a control.
doi:10.1371/journal.pone.0132498.g006
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mediators outcome from arachidonic acid (AA) and released by induced phospholipase A2
activity generate an amplification loop of the inflammation leading to a non-controlled
response. The involvement of sPLA2 IIA as a key regulator in chronic and acute inflammatory
diseases is well documented [44,12,45], likewise its major contribution through different path-
ways is clearly demonstrated in the arterial wall and VSMCs during atherosclerosis develop-
ment[46–47,39]. We have taken advantage of our expertise in the field of the transcriptional
regulation of the sPLA2 IIA gene expression in VSMCs to explore the action of AMPK signal-
ing pathway. AMPK originally thought to be a major survival factor in a variety of metabolic
stresses, appeared to be a critical downstream mediator of vascular adiponectin signaling [48].
In endothelial cells, it was shown that adiponectin inhibits CRP production through its ability
to modulate AMPK signaling pathways that in turn suppress NF-κB activity [49]. Furthermore,
AICAR reduces fatty acid-induced NF-κB activation [33] and diminishes endothelial cell pro-
liferation under conditions of ischemia [50]. Particularly interesting, metformin (the parent
phenformin biguanide) treatment of insulin resistant type 2 diabetic patients was proved to be
very effective for lessening macrovascular morbidity. Pre-treatment of HUVECs with metfor-
min was shown to have anti-inflammatory effects by suppressing TNF-α-induced IκBα degra-
dation through the AMPK pathway [51–52]. Metformin was first reported as an AMPK
agonist in hepatocytes [23], H-2K cells [51] and skeletal muscle [52] not acting through
changes in energy status. However, it was recently demonstrated that metformin-induced
changes in cellular AMP/ATP ratio is a pre-requisite for the activation of AMPK [30]. Particu-
larly interesting, it was shown that activation of AMPK by AICAR suppresses the proliferation
of human aortic SMCs by inducing S-15 phosphorylation and expression of p53. Induction of
CDKI p21 by AICAR suggested an AMPK-dependent G1 arrest through inactivation of E2F
transcription factor [34]. In the present study, we report that the expression of IL-1β-induced
sPLA2IIA mRNA in VSMCs was dose-dependently inhibited by phenformin and interestingly
also by resveratrol (trans-3,4’,5-trihydroxystilbene) (data not shown), a natural compound
known for its beneficial effect on cardiovascular system and activation of AMPK [53–54]. This
result confirms the protective activity of resveratrol in VSMCs likely by inhibiting transcription
factors such as NF-κB or AP-1 following the increase of AMPK activity [55–57]. In fine the
repressive effect that occurs through the AMPK signaling pathway affects a large coordinated
network of genes involved in the inflammatory amplification loop in VSMCs. In endothelial
cells, the mechanism by which metformin activates AMPK has been reported [58]
The inter-gene network of the genes affected by phenformin includes many transcription
factors and specifically the transcriptional repressor BCL-6 which targets many inflammatory
genes [22]. Here, we addressed the question about the action of AMPK on the transcriptional
repressor BCL-6 reported as a key regulator of sPLA2 IIa gene expression. AMPK activity
could in fine suppress inflammation through various mechanisms involving the stabilization of
repressive complexes on several inflammatory gene promoters. Recently, Gongol et al demon-
strated, in endothelial cells, that AMPKα2 facilitated the phosphorylation of PARP-1 and its
dissociation from the intron 1 of the repressor POZ/zinc-finger BCL-6 and hence led to the
extinction of inflammatory genes VCAM-1 and MCP-1 [59]
Nevertheless, to the best of our knowledge this is the first time that IL-1β-induced sPLA2
IIA activity is shown to be inhibited by AMPK activation mainly at a transcriptional level.
Since AMPK regulates the inhibition of a network of proinflammatory genes, we focused on
the molecular candidate repressor BCL-6 [60]. We previously demonstrated that sPLA2 IIA
gene is a direct target of BCL-6 acting through a specific binding site in the proximal promoter.
In accordance with the results reported by Lee et al [19] on another proinflammatory gene,
MCP1, we demonstrated that PPARβ activation by PPAR ligands led to the translocation of
the protooncogene BCL-6 and its binding to a specific site located between position -342 and
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-351bp relative to the transcription initiation start. BCL-6 could contribute to the prevention
of atherosclerosis by recruiting, with a high degree of overlap, SMRT and NCoR-corepressor
complexes to control the expression of inflammatory and atherogenic genes [61–62]. Precisely,
these studies revealed that BCL-6 SMRT/NCoR subcistromes are still enriched for proximally
bound NF-κB driven inflammatory and tissue remodelling genes in bone marrow of ldlr-/-
mice. Effectively, the sPLA2 IIA promoter contains NF-κB and C/EBP binding sites highly
conserved between rat and human (-131bp and 178bp respectively for rat and -138bp and
-235bp for human, unpublished results) and a typical BCL-6 binding site located at -340bp.
The organization of the sPLA2 IIA promoter is reminiscent of many promoters of inflamma-
tory genes where NF-κB and BCL-6 sites are co-localized within a 200bp space [21]. We also
observed in the present study that AMPK treatment stimulated BCL-6 expression and interest-
ingly, we confirm, as already observed by RT-PCR and western blotting analysis [18], that
BCL-6 is potentially an IL-1β-inducible transcriptional repressor, probably via the NF-κB
pathway. It was also shown that DNA binding activity or stability of the BCL-6 protein is mod-
ulated by several mechanisms [63–64,8] and that BCL-6 mediated a powerful repression
through a large set of interactions with tissue-specific repressors [65].
Interestingly, in contrast, to its action in the presence of the PPARβ ligand L165041, our
experiments with either phenformin or AICAR did not reveal a direct role for BCL-6. We
found that the mutation of the BCL-6 binding site on the sPLA2 promoter did not abolish the
repression, although the inhibition of the promoter following PPARβ activation by a synthetic
ligand was clearly dependent on BCL-6 DNA binding. A plausible mechanism could be that
AMPK activation targets more preferentially the IL-1β-induced transcription factors such as
NF-κB, C/EBPβ and AP1. According to this hypothesize transfection experiments revealed
that a multimeric NF-κB synthetic promoter was perfectly repressed by phenformin and
AICAR. In addition, we have shown that AMPK pathway also inhibits IL-1β phosphorylation
of IκBα. In accordance, it was recently demonstrated that AMPK could also play a key role in
endothelial cells as a pleiotropic inhibitor of immune response by acting through the nuclear
binding activity of the NF-κB transcription factor [41]. Indeed metformin was shown to inhibit
NF-κB activation by TNF-α and IL-1β via a possible AMPK pathway in endothelial cells and
VSMCs [66–67].In the present study we show that AMPK activation by AICAR or Phenformin
suppresses cytokine-induced NF-κB-dependent gene transcription and therefore modulates
inflammatory responses in VSMCs and contributes to the partial resolution of the inflamma-
tion. Thus the findings may have significance for treatment of atherosclerotic vascular disease.
At overall, our two studies on the transcriptional repression mechanisms of the IL-1β-
induced sPLA2 IIA promoter reveal at least two distinct pathways, one through the action of
the PPARβ ligand, as probably PGI2 eicosanoids, in liberating sequestrated BCL-6 which binds
to the BCL-6 consensus sequence and the second when AMPK is activated in blocking NF-B
activation complex. AMPK activation that occurs after phenformin treatment in VSMCs could
attenuate the recruitment of coactivators and inhibits IKK activity. Barroso et al. showed that
the PPARβ agonist, GW501516 prevented TNF–α-induced expression of NF-κB target genes
through AMPK activation by reducing the p300 and p65 interaction and by stimulating SIRT1
expression [63]. However, the existence of another non-exclusive inhibitory mechanisms medi-
ated by BCL-6 may occur in VSMCs. It was shown that the C-terminal domain of BCL-6 physi-
cally interacts with the Rel-homology domain of NF-κB in vitro as with AP1 family members
and that BCL-6 behaves as a mutual negative regulator of NF-κB target genes in diffuse large
B-cell lymphomas [68–69]. The present study did not demonstrate a repressible effect stimu-
lated by AMPK through a direct DNA binding of BCL-6, but may be consistent with a protein-
protein interaction with NF-κB complexes. This leads us to hypothesize a plausible mechanism
for the inhibition of the transcriptional activity of the sPLA2 IIA gene activity. In VSMCs,
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AMPK activation by phenformin could phosphorylate the DNA binding domain of BCL-6
which could hinder its binding to the sPLA2 IIA promoter located at -340 bp of the initiation
site without affecting its protein-protein interaction with the NF-κB transcriptional factor
located downstream at -131 bp. We postulate that, once phosphorylated, BCL-6 could stabilize
a SMRT/NCoR repressor complex that blocks IL-1β-induced NF-κB activity and then poten-
tially diminishes sPLA2 IIA gene transcription. In fact, our close examination of the BCL-6
sequence reveals a putative phosphorylation site by AMPK located between amino acids 11
and 16 in the N-terminal domain of BCL-6 which are conserved in human, rat, mouse and
chicken: FTRHASDVLL. This putative sequence matches well with the consensus one:
FxRxxSxxxL[69–70].
In addition, we cannot exclude the role of miRNA, such as miR-155, that in macrophages
was shown to repress the expression of BCL-6 in attenuating NF-κB signalling in advanced
atherosclerosis [71]. Interestingly, a cascade of mRNA targeted by miR-155 would be involved
in the regulation of vascular inflammation as described with the use of polyphenolic compound
as resveratrol [72].
The knowledge gained by this study about the sPLAIIA gene promoter will improve the
overall understanding of how cytokine-induced genes are regulated. On account of the closed
disposition of the regulatory elements, the study of the transcriptional activity of the promoter
will allow to identify new signalling pathways. A novel repression mechanism of the cytokine-
mediated induction of sPLA2 IIA in hepatocytes was recently deciphered [73]. The gene activ-
ity was blocked by the recruitment of corepressors SMRT and NCoR to the T3-liganded TRβ
bound to a non canonic site located between -102bp and -82bp, on the proximal region of the
rat sPLA2 IIA gene promoter. In fact, DNA binding interactions were precisely characterized
in the same mapped region (from -101 to -77bp) by DNA footprinting and EMSA assays with
VSMCs crude extracts (Antonio V. and Raymondjean M., unpublished results). This new
report and our present study show evidence about a network of positive and negative mecha-
nisms mediating the sPLA2 IIA promoter activity. The complexity and the overlapping of the
transcription factors highlight the crucial role played by the sPLA2 IIA in the control of cell
fate, i.e., proliferation, dedifferentiation and secretory status of VSMCs.
Interestingly, recently AMPK was shown to be the central target for the metabolic effects of
resveratrol in vivo by increasing the NAD to NADH ratio, thus contributing indirectly to the
stimulation of SIRT1 [74–75]. These evidences illustrate perfectly the central role played by the
fuel-sensing kinase activated by various metabolic and stress conditions. More recent studies
investigating the vascular consequences of AMPK deletion in vivo have shown that knockout
of AMPKα2 contributes to neointima formation after vascular injury and moreover, upregula-
tion of proinflammatory markers was observed in arteries of α1AMPK-knockout mice after
ATII infusion [76–77].
In summary, our study highlights the mutual exclusive regulation mechanism plays by
BCL-6 when therapeutic interventions by PPARβ ligands and antidiabetic drugs are adminis-
trated to patients Indisputably, more studies are needed to further understand how biguanide
molecules acting through the AMPK signaling pathway may have various beneficial metabolic
effects by reducing associated atherogenesis [78]. These results point to the sPLA2 IIA as a
potential therapeutic target for numerous inflammatory diseases.
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